JP2016104045A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104045A5
JP2016104045A5 JP2016043151A JP2016043151A JP2016104045A5 JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5 JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5
Authority
JP
Japan
Prior art keywords
cell
glycoprotein
seq
protein comprises
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016043151A
Other languages
English (en)
Other versions
JP2016104045A (ja
JP6211642B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104045A publication Critical patent/JP2016104045A/ja
Publication of JP2016104045A5 publication Critical patent/JP2016104045A5/ja
Application granted granted Critical
Publication of JP6211642B2 publication Critical patent/JP6211642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 改変を有するFXタンパク質を発現する細胞であって、該FXタンパク質は、配列番号1と少なくとも90%同一であるアミノ酸配列を含み、該改変は、位置289のセリンでの置換および位置90のリジンでの置換を含む、細胞。
  2. 前記FXタンパク質は、配列番号1と少なくとも95%同一であるアミノ酸配列を含む、請求項1に記載の細胞。
  3. 前記FXタンパク質は、位置289にセリンおよび位置90にリジンを有することを除いて、配列番号1と同一であるアミノ酸を含む、請求項1に記載の細胞。
  4. 前記FXタンパク質が、配列番号2を含む、請求項1に記載の細胞。
  5. 前記細胞が、チャイニーズハムスター卵巣(CHO)細胞である、請求項1〜4のいずれか一項に記載の細胞。
  6. 前記細胞が、糖タンパク質を発現する、請求項1〜5のいずれか一項に記載の細胞。
  7. 前記糖タンパク質が、抗体である、請求項6に記載の細胞。
  8. 前記細胞が37℃にて前記糖タンパク質をフコシル化する能力は、前記改変を欠く細胞によって呈される該糖タンパク質をフコシル化する能力の10%以下である、請求項6または7に記載の細胞。
  9. フコシル化の低下を有する糖タンパク質を作製するための方法であって、該方法は、
    (a)請求項1〜4のいずれか一項に記載の細胞を培養する工程であって、該細胞は糖タンパク質を発現する工程、および
    (b)該糖タンパク質を該培養物から単離する工程
    を含む、方法。
  10. 前記培養工程は、外部フコース供給源の非存在下で37℃の温度にて前記細胞を培養する工程をさらに含む、請求項9に記載の方法。
  11. 前記糖タンパク質が、免疫グロブリンCH2領域および免疫グロブリンCH3領域を含む、請求項9または10に記載の方法。
  12. 前記糖タンパク質が、抗体である、請求項11に記載の方法。
  13. 前記細胞が、チャイニーズハムスター卵巣(CHO)細胞である、請求項9〜12のいずれか一項に記載の方法。
  14. 前記糖タンパク質の6%以下がフコシル化される、請求項11に記載の方法。
  15. 前記糖タンパク質の2%以下がフコシル化される、請求項14に記載の方法。
JP2016043151A 2009-06-02 2016-03-07 フコシル化欠損細胞 Active JP6211642B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US61/183,400 2009-06-02
US34885810P 2010-05-27 2010-05-27
US61/348,858 2010-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014251541A Division JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202634A Division JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Publications (3)

Publication Number Publication Date
JP2016104045A JP2016104045A (ja) 2016-06-09
JP2016104045A5 true JP2016104045A5 (ja) 2016-12-01
JP6211642B2 JP6211642B2 (ja) 2017-10-11

Family

ID=42338231

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012514045A Active JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞
JP2016043151A Active JP6211642B2 (ja) 2009-06-02 2016-03-07 フコシル化欠損細胞
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012514045A Active JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Country Status (17)

Country Link
US (8) US8409838B2 (ja)
EP (3) EP2438171B1 (ja)
JP (4) JP5744856B2 (ja)
KR (2) KR101441437B1 (ja)
CN (1) CN102459603B (ja)
AU (1) AU2010256753B2 (ja)
BR (1) BRPI1010035A2 (ja)
CA (1) CA2764370C (ja)
DK (3) DK2808393T3 (ja)
ES (2) ES2661074T3 (ja)
HK (3) HK1163745A1 (ja)
HU (1) HUE038596T2 (ja)
IL (1) IL216624A (ja)
PL (3) PL3279326T3 (ja)
SG (1) SG176251A1 (ja)
TW (1) TWI513818B (ja)
WO (1) WO2010141478A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
ES2687771T3 (es) 2011-03-06 2018-10-29 Merck Serono Sa Líneas de células con bajo nivel de fucosa y sus usos
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
HUE045307T2 (hu) 2014-03-11 2019-12-30 Regeneron Pharma EGFRVIII-ellenes antitestek és alkalmazásaik
KR20170012286A (ko) * 2014-05-30 2017-02-02 뉴 잉글랜드 바이오랩스, 인크 탈당화 시약 및 방법
SG11201610699XA (en) * 2014-07-07 2017-01-27 Targazyme Inc Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017079165A1 (en) * 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
CA3010598A1 (en) 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
CA3110254C (en) * 2018-08-29 2023-08-29 United Biopharma Inc Afucosylated antibodies and manufacture thereof
KR20210084488A (ko) 2018-10-29 2021-07-07 가부시키가이샤 멘에키세이부츠 켄큐죠 항hiv항체 및 그 제조 방법
JP2023527352A (ja) 2020-05-26 2023-06-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
CN116057069A (zh) 2020-06-03 2023-05-02 瑞泽恩制药公司 用抗SARS-CoV-2刺突糖蛋白抗体治疗或预防SARS-CoV-2感染和COVID-19的方法
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
US20240010737A1 (en) 2022-03-02 2024-01-11 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1914244E (pt) * 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2785941C (en) * 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
DE60211329T2 (de) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
US20100028951A1 (en) 2007-03-07 2010-02-04 Stephen Hamilton Production of glycoproteins with modified fucosylation
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP5662149B2 (ja) 2008-08-13 2015-01-28 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
KR101441437B1 (ko) 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
ES2687771T3 (es) 2011-03-06 2018-10-29 Merck Serono Sa Líneas de células con bajo nivel de fucosa y sus usos

Similar Documents

Publication Publication Date Title
JP2016104045A5 (ja)
AR120511A2 (es) Producción de proteínas heteromultiméricas
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
JP2019505164A5 (ja)
MY189819A (en) Genetically modified cells and uses thereof
BR112018008648A2 (pt) métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t
MX2019008417A (es) Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas.
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
GB201003701D0 (en) System for the expression of a protein
JP2017505620A5 (ja)
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
JP2015532096A5 (ja)
EA202091349A1 (ru) Способы культивирования клеток
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
RU2015129656A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
BR112016028538A2 (pt) processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo
BR112016023980A2 (pt) anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)
WO2012173344A3 (ko) Csp-b 5'-sar 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법
MX2019007924A (es) Vacunas contra la influenza.
SG11201902998SA (en) PROMOTER OF Hspa5 GENE
JP2016512251A5 (ja)
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
BR112017017303B8 (pt) Método para obtenção de clones de células de alta produtividade
JP2015536347A5 (ja)